Logo image of BODI

BEACHBODY CO INC/THE (BODI) Stock Fundamental Analysis

NYSE:BODI - New York Stock Exchange, Inc. - US0734633094 - Common Stock - Currency: USD

3.75  -0.5 (-11.76%)

Fundamental Rating

1

Overall BODI gets a fundamental rating of 1 out of 10. We evaluated BODI against 73 industry peers in the Diversified Consumer Services industry. BODI may be in some trouble as it scores bad on both profitability and health. BODI is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

BODI had negative earnings in the past year.
BODI had a positive operating cash flow in the past year.
BODI had negative earnings in each of the past 5 years.
In multiple years BODI reported negative operating cash flow during the last 5 years.
BODI Yearly Net Income VS EBIT VS OCF VS FCFBODI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M

1.2 Ratios

Looking at the Return On Assets, with a value of -41.04%, BODI is doing worse than 73.97% of the companies in the same industry.
BODI has a worse Return On Equity (-254.32%) than 72.60% of its industry peers.
Industry RankSector Rank
ROA -41.04%
ROE -254.32%
ROIC N/A
ROA(3y)-46.66%
ROA(5y)-36.36%
ROE(3y)-176.86%
ROE(5y)-122.28%
ROIC(3y)N/A
ROIC(5y)N/A
BODI Yearly ROA, ROE, ROICBODI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200 -250

1.3 Margins

BODI has a Gross Margin of 68.61%. This is amongst the best in the industry. BODI outperforms 86.30% of its industry peers.
In the last couple of years the Gross Margin of BODI has remained more or less at the same level.
BODI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.61%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.22%
GM growth 5Y-1.01%
BODI Yearly Profit, Operating, Gross MarginsBODI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

1

2. Health

2.1 Basic Checks

BODI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BODI has been increased compared to 1 year ago.
Compared to 5 years ago, BODI has less shares outstanding
The debt/assets ratio for BODI is higher compared to a year ago.
BODI Yearly Shares OutstandingBODI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 100M 200M 300M
BODI Yearly Total Debt VS Total AssetsBODI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of -3.72, we must say that BODI is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -3.72, BODI is not doing good in the industry: 73.97% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.34 indicates that BODI is not too dependend on debt financing.
BODI has a Debt to Equity ratio of 0.34. This is comparable to the rest of the industry: BODI outperforms 49.32% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF N/A
Altman-Z -3.72
ROIC/WACCN/A
WACC11.99%
BODI Yearly LT Debt VS Equity VS FCFBODI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M

2.3 Liquidity

A Current Ratio of 0.62 indicates that BODI may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.62, BODI is doing worse than 72.60% of the companies in the same industry.
A Quick Ratio of 0.49 indicates that BODI may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.49, BODI is doing worse than 76.71% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.62
Quick Ratio 0.49
BODI Yearly Current Assets VS Current LiabilitesBODI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 46.86% over the past year.
BODI shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -20.55%.
BODI shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -11.14% yearly.
EPS 1Y (TTM)46.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-26.95%
Revenue 1Y (TTM)-20.55%
Revenue growth 3Y-21.74%
Revenue growth 5Y-11.14%
Sales Q2Q%-27.42%

3.2 Future

The Earnings Per Share is expected to grow by 22.74% on average over the next years. This is a very strong growth
Based on estimates for the next years, BODI will show a very negative growth in Revenue. The Revenue will decrease by -23.57% on average per year.
EPS Next Y49.23%
EPS Next 2Y22.74%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-40.89%
Revenue Next 2Y-23.57%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
BODI Yearly Revenue VS EstimatesBODI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 200M 400M 600M 800M
BODI Yearly EPS VS EstimatesBODI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -5 -10 -15 -20 -25

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BODI. In the last year negative earnings were reported.
Also next year BODI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BODI Price Earnings VS Forward Price EarningsBODI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

BODI's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BODI is cheaper than 93.15% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 2.88
BODI Per share dataBODI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40

4.3 Compensation for Growth

A more expensive valuation may be justified as BODI's earnings are expected to grow with 22.74% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.74%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BODI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BEACHBODY CO INC/THE

NYSE:BODI (4/30/2025, 8:04:01 PM)

3.75

-0.5 (-11.76%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Services
GICS IndustryDiversified Consumer Services
Earnings (Last)03-27 2025-03-27/amc
Earnings (Next)05-12 2025-05-12/amc
Inst Owners40.81%
Inst Owner ChangeN/A
Ins Owners4.78%
Ins Owner Change7.47%
Market Cap26.21M
Analysts82.22
Price Target10.79 (187.73%)
Short Float %5.27%
Short Ratio11.69
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-13.18%
Min EPS beat(2)-77.42%
Max EPS beat(2)51.05%
EPS beat(4)2
Avg EPS beat(4)-2.51%
Min EPS beat(4)-77.42%
Max EPS beat(4)51.05%
EPS beat(8)3
Avg EPS beat(8)-11.63%
EPS beat(12)4
Avg EPS beat(12)-19.99%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)1.22%
Min Revenue beat(2)-2.88%
Max Revenue beat(2)5.31%
Revenue beat(4)2
Avg Revenue beat(4)0.6%
Min Revenue beat(4)-2.88%
Max Revenue beat(4)5.31%
Revenue beat(8)4
Avg Revenue beat(8)1.02%
Revenue beat(12)6
Avg Revenue beat(12)1.06%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-19.43%
PT rev (3m)-19.43%
EPS NQ rev (1m)-56.04%
EPS NQ rev (3m)-56.04%
EPS NY rev (1m)-26.89%
EPS NY rev (3m)-26.89%
Revenue NQ rev (1m)-22.04%
Revenue NQ rev (3m)-22.04%
Revenue NY rev (1m)-20.55%
Revenue NY rev (3m)-20.55%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.06
P/FCF N/A
P/OCF 10.23
P/B 0.93
P/tB N/A
EV/EBITDA 2.88
EPS(TTM)-9.55
EYN/A
EPS(NY)-4.85
Fwd EYN/A
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)0.37
OCFY9.77%
SpS59.91
BVpS4.03
TBVpS-7.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -41.04%
ROE -254.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.61%
FCFM N/A
ROA(3y)-46.66%
ROA(5y)-36.36%
ROE(3y)-176.86%
ROE(5y)-122.28%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.22%
GM growth 5Y-1.01%
F-Score6
Asset Turnover2.4
Health
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF N/A
Debt/EBITDA 1.11
Cap/Depr 9.64%
Cap/Sales 1.08%
Interest Coverage N/A
Cash Conversion 29.3%
Profit Quality N/A
Current Ratio 0.62
Quick Ratio 0.49
Altman-Z -3.72
F-Score6
WACC11.99%
ROIC/WACCN/A
Cap/Depr(3y)15.58%
Cap/Depr(5y)44.94%
Cap/Sales(3y)2.05%
Cap/Sales(5y)3.89%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-26.95%
EPS Next Y49.23%
EPS Next 2Y22.74%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-20.55%
Revenue growth 3Y-21.74%
Revenue growth 5Y-11.14%
Sales Q2Q%-27.42%
Revenue Next Year-40.89%
Revenue Next 2Y-23.57%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y58.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year136.27%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y93.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y111.37%
OCF growth 3YN/A
OCF growth 5Y-42.85%